RA
RVMD icon

Rise Advisors’s Revolution Medicines RVMD Stock Holding History

Rise Advisors’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-365
Closed -$17K – 1170
2025
Q3 		$17K Hold
365
– – 0.01% 673
2025
Q2 		$13.4K Hold
365
– – 0.01% 812
2025
Q1 		$12.9K Buy
+365
New +$14.8K 0.01% 800

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Rise Advisors's RVMD Position: Q4 2025 in Review

Rise Advisors sold out of Revolution Medicines (RVMD) in Q4 2025, closing a stake of 365 shares — an estimated $17K sold.

Rise Advisors first reported a position in RVMD in Q1 2025 and held it in 3 quarters. The position peaked at $17K in Q3 2025. 386 funds tracked by Wall St. Rank hold RVMD as of Q4 2025.

  • Rise Advisors reported no remaining Revolution Medicines position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 365 Revolution Medicines shares in Q4 2025, an estimated $17K.
  • Rise Advisors first reported a position in Revolution Medicines in Q1 2025 and held it in 3 quarters.
  • Rise Advisors's Revolution Medicines position peaked at $17K in Q3 2025.
  • 386 funds tracked by Wall St. Rank held Revolution Medicines as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.